Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

@inproceedings{Bedimo2011GrowthHA,
  title={Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy},
  author={Roger J. Bedimo},
  booktitle={HIV/AIDS},
  year={2011}
}
HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause significant patient distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment options - including antiretroviral switch, insulin sensitizers, and surgical approaches - have been associated with limited success and potential… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 86 REFERENCES

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

  • The New England journal of medicine
  • 2007
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective REAL study

GJ Moyle, JM Girard, J. Andrade
  • XVII International AIDS Conference. Mexico City,
  • 2008
VIEW 2 EXCERPTS